Merus to Participate in a Fireside Chat at the Jefferies London Healthcare Conference (Virtual)

Rhea-AI Summary

Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company, has announced that CEO Bill Lundberg, M.D., will participate in a fireside chat at the Jefferies London Healthcare Conference. This virtual event is scheduled for November 18, 2021, and the prerecorded session will be available on the Company's investor webpage at 8:00 am GMT/3:00 am ET. Merus is known for developing innovative multispecific antibody therapeutics, Biclonics and Triclonics, which show potential advantages similar to conventional human monoclonal antibodies.

News Market Reaction – MRUS

+2.95%

+2.95% Session move

In the trading session that priced this news, MRUS gained 2.95%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics^®), today announced that Bill Lundberg, M.D., Chief Executive Officer of Merus, will participate in a fireside chat at the Jefferies London Healthcare Conference (Virtual).

The prerecorded fireside chat will be available starting on Thursday, November 18, 2021 at 8:00 am GMT/3:00 am ET on the Investors page of the Company's website and remain available for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and twitter.

FAQ

What event will Merus's CEO participate in on November 18, 2021?

Merus's CEO, Bill Lundberg, will participate in a fireside chat at the Jefferies London Healthcare Conference.

When can I watch the Merus virtual fireside chat?

The prerecorded fireside chat will be available starting on November 18, 2021, at 8:00 am GMT/3:00 am ET.

Where can I find the Merus fireside chat video?

The fireside chat video will be available on the Investors page of Merus's website.

What is Merus known for?

Merus is known for developing innovative full-length multispecific antibody therapeutics, including Biclonics and Triclonics.

What is the focus of Merus's research and development?

Merus focuses on oncology, developing multispecific antibodies that aim to improve treatment outcomes.